Who are Intratracheal administration of surfactant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Curosurf, Infasurf, Survanta, Colace, Budesonide-Surfactant, Poractant alfa (Curosurf®).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intratracheal-administration-of-surfactant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intratracheal administration of surfactant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intratracheal administration of surfactant (Intratracheal administration of surfactant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Surfactant. Area: Respiratory.

phase 2 Surfactant Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Intratracheal administration of surfactant (Intratracheal administration of surfactant) — Chiesi Poland Sp. z o.o.. Surfactant replacement therapy

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intratracheal administration of surfactant TARGET	Intratracheal administration of surfactant	Chiesi Poland Sp. z o.o.	phase 2	Surfactant
Curosurf	PORACTANT ALFA	Chiesi Usa Inc	marketed	Surfactant [EPC]		1999-01-01
Infasurf	CALFACTANT	ONY	marketed	Surfactant [EPC]		1998-01-01
Survanta	BERACTANT	AbbVie	marketed	Surfactant [EPC]		1991-01-01
Colace	docusate sodium	Generic (multiple manufacturers)	marketed	Stool softener (surfactant laxative)	N/A (surfactant mechanism)	1955-01-01
Budesonide-Surfactant	Budesonide-Surfactant	China Medical University Hospital	marketed	Inhaled corticosteroid with surfactant excipient	Glucocorticoid receptor
Poractant alfa (Curosurf®)	Poractant alfa (Curosurf®)	Chiesi Farmaceutici S.p.A.	marketed	Pulmonary surfactant replacement therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Surfactant class)

Chiesi Poland Sp. z o.o. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intratracheal administration of surfactant — Competitive Intelligence Brief. https://druglandscape.com/ci/intratracheal-administration-of-surfactant. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab